Logo

TARA

Protara Therapeutics, Inc.

TARA

Protara Therapeutics, Inc. • NASDAQ
$7.38 ▼ -0.34% (-0.03)
Market Cap $284.77 M
52w High $10.48
52w Low $2.48
Dividend Yield 0%
P/E -5.31
Volume 309.79K
Outstanding Shares 38.59M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $14.672M ▼ $-13.258M ▲ 0% $-0.31 ▲ $-11.668M ▲
Q2-2025 $0 $16.586M ▲ $-14.96M ▼ 0% $-0.35 ▼ $-16.488M ▼
Q1-2025 $0 $14.124M ▼ $-11.914M ▲ 0% $-0.29 ▲ $-14.041M ▲
Q4-2024 $0 $14.312M ▲ $-12.769M ▼ 0% $-0.48 ▲ $-14.23M ▼
Q3-2024 $0 $12.33M $-11.219M 0% $-0.5 $-12.246M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $132.67M ▲ $144.636M ▼ $12.345M ▼ $132.291M ▼
Q2-2025 $122.216M ▼ $156.933M ▼ $12.51M ▲ $144.423M ▼
Q1-2025 $124.363M ▼ $168.559M ▼ $10.075M ▼ $158.484M ▼
Q4-2024 $170.292M ▲ $181.454M ▲ $14.32M ▲ $167.134M ▲
Q3-2024 $81.499M $94.09M $12.299M $81.791M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-13.258M ▲ $-12.452M ▼ $-6.506M ▲ $13K ▲ $-18.945M ▲ $-12.456M ▼
Q2-2025 $-14.96M ▼ $-12.25M ▲ $-47.723M ▲ $8K ▼ $-59.965M ▲ $-12.272M ▲
Q1-2025 $-11.914M ▲ $-14.713M ▼ $-58.354M ▼ $1.73M ▼ $-71.337M ▼ $-14.757M ▼
Q4-2024 $-12.769M ▼ $-9.308M ▼ $22.5M ▲ $97.849M ▲ $111.041M ▲ $-9.308M ▼
Q3-2024 $-11.219M $-8.434M $-29.39M $0 $-37.824M $-8.442M

Five-Year Company Overview

Income Statement

Income Statement Protara is still a pre‑revenue biotech, so there is no product sales yet and all activity shows up as research and operating costs. The company has reported steady losses for years, which is typical for a clinical‑stage firm funding trials before commercialization. The size of the losses appears manageable and has recently narrowed somewhat on a per‑share basis, but the business model remains entirely dependent on external funding and future trial success rather than current earnings.

Balance Sheet

Balance Sheet The balance sheet is relatively simple and lean. Assets are small but mostly made up of cash, with very little debt, which limits financial strain from interest payments. Shareholders’ equity remains positive, though it has been eroded over time by ongoing losses. The recent improvement in the cash balance suggests the company has refreshed its funding, but the capital base is still modest, so the balance sheet is adequate for a small clinical program, not yet built for large‑scale commercialization.

Cash Flow

Cash Flow Cash flow is consistently negative, driven by research and development and general operating expenses, with essentially no spending on heavy equipment or facilities. This means most cash burn is directly tied to advancing the pipeline rather than to fixed assets. While the burn rate looks controlled for a biotech, the company still relies on raising capital or forming partnerships to fund operations over time, and that dependency will continue until at least one program reaches approval or meaningful partnering revenue.

Competitive Edge

Competitive Edge Protara’s competitive edge comes from focusing on underserved niches. TARA‑002 targets bladder cancer patients who cannot benefit from the long‑standing standard BCG treatment, as well as a rare pediatric lymphatic condition, both of which have meaningful unmet needs. Early trial results in bladder cancer appear encouraging, and regulatory designations support faster review and potential exclusivity. IV Choline Chloride aims at a clear gap—parenteral nutrition patients who lack an approved intravenous choline option—offering a potential first‑mover position protected by patents. On the other side, Protara is a small player facing larger oncology and hospital‑nutrition competitors, with no proven commercial infrastructure, so its ultimate market position will depend heavily on clinical outcomes and its ability to secure strong partners or build a commercial footprint.

Innovation and R&D

Innovation and R&D The company is highly research‑driven, with its value concentrated in two main programs. TARA‑002 is a cell‑based immunotherapy designed to broadly stimulate the immune system, building on an existing product used in Asia, which provides a scientific and clinical foundation. The early bladder cancer data suggest meaningful responses with a tolerable safety profile, and the rare pediatric designation in lymphatic malformations adds potential upside. IV Choline Chloride is more of a foundational supportive‑care therapy, intended to correct a well‑recognized nutrient deficiency in long‑term parenteral nutrition patients, and now has a clear registrational trial path agreed with regulators. The flip side is concentration risk: progress depends heavily on these few assets, and any clinical, regulatory, or safety setbacks could sharply reduce the company’s prospects.

Summary

Protara is a classic early‑stage biotech: no revenue yet, ongoing but controlled losses, and a balance sheet that is primarily cash‑funded with minimal debt. Its story is almost entirely about pipeline execution. The strengths are a focused strategy on meaningful unmet needs, promising early data in bladder cancer, a potentially first‑in‑class IV choline product, supportive regulatory designations, and patents that extend protection well into the next decade. Key risks center on clinical and regulatory uncertainty, heavy dependence on two lead programs, the need for continued external financing, and competition from larger, better‑resourced companies if its products reach the market. Overall, the company offers high potential but also high uncertainty, typical of a small, clinical‑stage biotech still several key milestones away from a stable commercial business.

NEWS

November 19, 2025 · 8:00 AM UTC

Protara Therapeutics Announces Positive Interim Results Demonstrating Robust Responses in the Ongoing Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

Read more

November 18, 2025 · 4:30 PM UTC

Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations on Wednesday, November 19, 2025

Read more

November 17, 2025 · 8:00 AM UTC

Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the 26th Annual Meeting of the Society of Urologic Oncology

Read more

November 10, 2025 · 8:00 AM UTC

Protara Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

Read more

November 4, 2025 · 4:05 PM UTC

Protara Therapeutics Named a 2026 Best Places to Work Winner by BioSpace

Read more